Botulinum Neurotoxin BoNT-A in the Management of Hypertrophic Scars and Keloids: A Comprehensive Review

REVIEW
Ramadan S. Hussein

 
For citation: Hussein RS. Botulinum Neurotoxin BoNT-A in the Management of Hypertrophic Scars and Keloids: A Comprehensive Review. International Journal of Biomedicine. 2024;14(1):15-19. doi:10.21103/Article14(1)_RA2
 
Originally published March 1, 2024

Abstract: 

Hypertrophic scars (HS) and keloids are challenging dermatological conditions that often lead to physical and psychological distress in affected individuals. Current therapeutic approaches have limitations, prompting the exploration of novel treatments. Botulinum Neurotoxin BoNT-A has emerged as a promising candidate in managing these scars. This comprehensive review delves into the pathophysiology of HS and keloids, the shortcomings of existing treatments, and the mechanisms underlying BoNT-A's potential efficacy. Through an analysis of clinical studies and evidence, the review evaluates BoNT-A's impact on scar formation and patient outcomes. Safety and side effects and the potential influence of BoNT-A on quality of life are also considered. Comparative analysis with traditional therapies underscores the advantages and challenges of BoNT-A use. The review concludes by suggesting future research directions and emphasizing the significance of Botulinum Neurotoxin BoNT-A as a promising therapeutic option. This article provides valuable insights for clinicians, researchers, and patients seeking innovative solutions for HS and keloids.

Keywords: 
hypertrophic scars • keloids • botulinum neurotoxin
References: 
  1. Olaitan PB. Keloids: assessment of effects and psychosocial-impacts on subjects in a black African population. Indian J Dermatol Venereol Leprol. 2009 Jul-Aug;75(4):368-72. doi: 10.4103/0378-6323.53132.
  2. Viera MH, Caperton CV, Berman B. Advances in the treatment of keloids. J Drugs Dermatol. 2011 May;10(5):468-80. 
  3. Fanous A, Bezdjian A, Caglar D, Mlynarek A, Fanous N, Lenhart SF, Daniel SJ. Treatment of Keloid Scars with Botulinum Toxin Type A versus Triamcinolone in an Athymic Nude Mouse Model. Plast Reconstr Surg. 2019 Mar;143(3):760-767. doi: 10.1097/PRS.0000000000005323. 
  4. Bi M, Sun P, Li D, Dong Z, Chen Z. Intralesional Injection of Botulinum Toxin Type A Compared with Intralesional Injection of Corticosteroid for the Treatment of Hypertrophic Scar and Keloid: A Systematic Review and Meta-Analysis. Med Sci Monit. 2019 Apr 22;25:2950-2958. doi: 10.12659/MSM.916305. 
  5. Gurtner GC, Werner S, Barrandon Y, Longaker MT. Wound repair and regeneration. Nature. 2008 May 15;453(7193):314-21. doi: 10.1038/nature07039. 
  6. Driskell RR, Lichtenberger BM, Hoste E, Kretzschmar K, Simons BD, Charalambous M, Ferron SR, Herault Y, Pavlovic G, Ferguson-Smith AC, Watt FM. Distinct fibroblast lineages determine dermal architecture in skin development and repair. Nature. 2013 Dec 12;504(7479):277-281. doi: 10.1038/nature12783.
  7. Gauglitz GG, Korting HC, Pavicic T, Ruzicka T, Jeschke MG. Hypertrophic scarring and keloids: pathomechanisms and current and emerging treatment strategies. Mol Med. 2011 Jan-Feb;17(1-2):113-25. doi: 10.2119/molmed.2009.00153. 
  8. Slemp AE, Kirschner RE. Keloids and scars: a review of keloids and scars, their pathogenesis, risk factors, and management. Curr Opin Pediatr. 2006 Aug;18(4):396-402. doi: 10.1097/01.mop.0000236389.41462.ef.
  9. Marshall CD, Hu MS, Leavitt T, Barnes LA, Lorenz HP, Longaker MT. Cutaneous Scarring: Basic Science, Current Treatments, and Future Directions. Adv Wound Care (New Rochelle). 2018 Feb 1;7(2):29-45. doi: 10.1089/wound.2016.0696. 
  10. Lim AF, Weintraub J, Kaplan EN, Januszyk M, Cowley C, McLaughlin P, Beasley B, Gurtner GC, Longaker MT. The embrace device significantly decreases scarring following scar revision surgery in a randomized controlled trial. Plast Reconstr Surg. 2014 Feb;133(2):398-405. doi: 10.1097/01.prs.0000436526.64046.d0.
  11. Anzarut A, Olson J, Singh P, Rowe BH, Tredget EE. The effectiveness of pressure garment therapy for the prevention of abnormal scarring after burn injury: a meta-analysis. J Plast Reconstr Aesthet Surg. 2009 Jan;62(1):77-84. doi: 10.1016/j.bjps.2007.10.052. 
  12. Thomas JR, Somenek M. Scar revision review. Arch Facial Plast Surg. 2012 May-Jun;14(3):162-74. doi: 10.1001/archfacial.2012.223.
  13. Malhotra AK, Gupta S, Khaitan BK, Sharma VK. Imiquimod 5% cream for the prevention of recurrence after excision of presternal keloids. Dermatology. 2007;215(1):63-5. doi: 10.1159/000102036. 
  14. Nouri K, Elsaie ML, Vejjabhinanta V, Stevens M, Patel SS, Caperton C, Elgart G. Comparison of the effects of short- and long-pulse durations when using a 585-nm pulsed dye laser in the treatment of new surgical scars. Lasers Med Sci. 2010 Jan;25(1):121-6. doi: 10.1007/s10103-009-0710-3.
  15. Shockley WW. Scar revision techniques: z-plasty, w-plasty, and geometric broken line closure. Facial Plast Surg Clin North Am. 2011 Aug;19(3):455-63. doi: 10.1016/j.fsc.2011.06.002.
  16. Dressler D, Adib Saberi F. Botulinum toxin: mechanisms of action. Eur Neurol. 2005;53(1):3-9. doi: 10.1159/000083259. 
  17. Ramot Y, Böhm M, Paus R. Translational Neuroendocrinology of Human Skin: Concepts and Perspectives. Trends Mol Med. 2021 Jan;27(1):60-74. doi: 10.1016/j.molmed.2020.09.002. 
  18. Ogawa R, Okai K, Tokumura F, Mori K, Ohmori Y, Huang C, Hyakusoku H, Akaishi S. The relationship between skin stretching/contraction and pathologic scarring: the important role of mechanical forces in keloid generation. Wound Repair Regen. 2012 Mar-Apr;20(2):149-57. doi: 10.1111/j.1524-475X.2012.00766.x. 
  19. Hao R, Li Z, Chen X, Ye W. Efficacy and possible mechanisms of Botulinum Toxin type A on hypertrophic scarring. J Cosmet Dermatol. 2018 Jun;17(3):340-346. doi: 10.1111/jocd.12534. 
  20. Fanous A, Bezdjian A, Caglar D, Mlynarek A, Fanous N, Lenhart SF, Daniel SJ. Treatment of Keloid Scars with Botulinum Toxin Type A versus Triamcinolone in an Athymic Nude Mouse Model. Plast Reconstr Surg. 2019 Mar;143(3):760-767. doi: 10.1097/PRS.0000000000005323. 
  21. Shaarawy E, Hegazy RA, Abdel Hay RM. Intralesional botulinum toxin type A equally effective and better tolerated than intralesional steroid in the treatment of keloids: a randomized controlled trial. J Cosmet Dermatol. 2015 Jun;14(2):161-6. doi: 10.1111/jocd.12134. 
  22. Rasaii S, Sohrabian N, Gianfaldoni S, Hadibarhaghtalab M, Pazyar N, Bakhshaeekia A, Lotti T, Ramirez-Pacheco LA, Lange CS, Matta J, Seifi V, Ramirez-Fort MK, Feily A. Intralesional triamcinolone alone or in combination with botulinium toxin A is ineffective for the treatment of formed keloid scar: A double blind controlled pilot study. Dermatol Ther. 2019 Mar;32(2):e12781. doi: 10.1111/dth.12781.
  23. Li J, Wu X, Chen X. Observation on clinical efficacy of intralesional injection of glucocorticoid combined with botulinum toxin type A for treatment of keloid. J Clin Dermatology. 2017; 46:629–635.
  24. ZHOU Mingwei, WANG Lianyou, JIANG Rihua, ZHU Mingji, CHEN Feng. Evaluation on efficacy and adverse reactions of combined therapy with botulinum toxin type A in treatment of keloid. Journal of Jilin University Medicine Edition, 2017, 43(02): 386-390.
  25. Zhibo X, Miaobo Z. Intralesional botulinum toxin type A injection as a new treatment measure for keloids. Plast Reconstr Surg. 2009 Nov;124(5):275e-277e. doi: 10.1097/PRS.0b013e3181b98ee7.
  26. Gauglitz GG, Bureik D, Dombrowski Y, Pavicic T, Ruzicka T, Schauber J. Botulinum toxin A for the treatment of keloids. Skin Pharmacol Physiol. 2012;25(6):313-8. doi: 10.1159/000342125. 
  27. Pruksapong C, Yingtaweesittikul S, Burusapat C. Efficacy of Botulinum Toxin A in Preventing Recurrence Keloids: Double Blinded Randomized Controlled Trial Study: Intraindividual Subject. J Med Assoc Thai. 2017 Mar;100(3):280-6. 
  28.  Lee SH, Min HJ, Kim YW, Cheon YW. The Efficacy and Safety of Early Postoperative Botulinum Toxin A Injection for Facial Scars. Aesthetic Plast Surg. 2018 Apr;42(2):530-537. doi: 10.1007/s00266-017-1008-7.
  29. Koonce S, Lloreda A and Stelnicki E. Long-term results of the use of botox as an adjunct for cleft lip reconstruction. Cleft Palate–Craniofacial J. 2017;54:e59. 24.
  30. Li YH, Yang J, Liu JQ, Xie ST, Zhang YJ, Zhang W, Zhang JL, Zheng Z, Hu DH. A Randomized, Placebo-Controlled, Double-Blind, Prospective Clinical Trial of Botulinum Toxin Type A in Prevention of Hypertrophic Scar Development in Median Sternotomy Wound. Aesthetic Plast Surg. 2018 Oct;42(5):1364-1369. doi: 10.1007/s00266-018-1187-x. 

Download Article
Received November 6, 2023.
Accepted December 20, 2023.
©2024 International Medical Research and Development Corporation.